Tabernero J - Search Results

1

Evaluation of aflibercept in the treatment of metastatic colorectal cancer.

Macarulla T, Sauri T, Tabernero J. Macarulla T, et al. Among authors: tabernero j. Expert Opin Biol Ther. 2014 Oct;14(10):1493-505. doi: 10.1517/14712598.2014.947956. Epub 2014 Aug 25. Expert Opin Biol Ther. 2014. PMID: 25152076 Review.

2

Lack of efficacy of streptozocin and doxorubicin in patients with advanced pancreatic endocrine tumors.

Vilar E, Tabernero J, Casado E, Macarulla T, Ramos FJ, Martinelli E, Saura C. Vilar E, et al. Among authors: tabernero j. Am J Clin Oncol. 2005 Aug;28(4):424. doi: 10.1097/01.coc.0000162426.79311.a5. Am J Clin Oncol. 2005. PMID: 16062087 No abstract available.

3

Emerging trends in combinations of gefitinib and cytotoxic agents: new opportunities.

Tabernero J, Macarulla T. Tabernero J, et al. Onkologie. 2005 Oct;28(10):467-70. doi: 10.1159/000088154. Onkologie. 2005. PMID: 16285032 Free article. No abstract available.

4

Epidermal growth factor receptor (EGFR) inhibitors in gastrointestinal cancer.

Macarulla T, Casado E, Ramos FJ, Valverde C, Tabernero J. Macarulla T, et al. Among authors: tabernero j. Onkologie. 2006 Mar;29(3):99-105. doi: 10.1159/000091013. Epub 2006 Mar 3. Onkologie. 2006. PMID: 16514271 Review.

5

Novel targets in gastric and esophageal cancer.

Valverde CM, Macarulla T, Casado E, Ramos FJ, Martinelli E, Tabernero J. Valverde CM, et al. Among authors: tabernero j. Crit Rev Oncol Hematol. 2006 Aug;59(2):128-38. doi: 10.1016/j.critrevonc.2006.02.001. Epub 2006 Jul 10. Crit Rev Oncol Hematol. 2006. PMID: 16829119

6

Novel targets for anticancer treatment development in colorectal cancer.

Macarulla T, Ramos FJ, Capdevila J, Saura C, Tabernero J. Macarulla T, et al. Among authors: tabernero j. Clin Colorectal Cancer. 2006 Nov;6(4):265-72. doi: 10.3816/CCC.2006.n.045. Clin Colorectal Cancer. 2006. PMID: 17241511 Review.

7

The role of VEGF and EGFR inhibition: implications for combining anti-VEGF and anti-EGFR agents.

Tabernero J. Tabernero J. Mol Cancer Res. 2007 Mar;5(3):203-20. doi: 10.1158/1541-7786.MCR-06-0404. Mol Cancer Res. 2007. PMID: 17374728 Review.

8

New approaches in systemic treatment of advanced colorectal cancer: the molecular targets era.

Capdevila J, Mendez G, Macarulla T, Ramos FJ, Casado E, Tabernero J. Capdevila J, et al. Among authors: tabernero j. Expert Rev Anticancer Ther. 2007 Jul;7(7):1027-41. doi: 10.1586/14737140.7.7.1027. Expert Rev Anticancer Ther. 2007. PMID: 17627462 Review.

9

Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer.

Tabernero J, Van Cutsem E, Díaz-Rubio E, Cervantes A, Humblet Y, André T, Van Laethem JL, Soulié P, Casado E, Verslype C, Valera JS, Tortora G, Ciardiello F, Kisker O, de Gramont A. Tabernero J, et al. J Clin Oncol. 2007 Nov 20;25(33):5225-32. doi: 10.1200/JCO.2007.13.2183. J Clin Oncol. 2007. PMID: 18024868 Clinical Trial.

10

Administration of cetuximab every 2 weeks in the treatment of metastatic colorectal cancer: an effective, more convenient alternative to weekly administration?

Tabernero J, Pfeiffer P, Cervantes A. Tabernero J, et al. Oncologist. 2008 Feb;13(2):113-9. doi: 10.1634/theoncologist.2007-0201. Oncologist. 2008. PMID: 18305055 Free article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

840 results

Search Page

Filters